Related references
Note: Only part of the references are listed.KRAS Mutation in Patients Undergoing Hepatic Resection for Colorectal Liver Metastasis: A Biomarker of Cancer Biology or a Byproduct of Patient Selection?
Kjetil Soreide et al.
CANCER (2014)
KRAS Mutation Influences Recurrence Patterns in Patients Undergoing Hepatic Resection of Colorectal Metastases
Nancy E. Kemeny et al.
CANCER (2014)
RAS Mutation Status Predicts Survival and Patterns of Recurrence in Patients Undergoing Hepatectomy for Colorectal Liver Metastases
Jean-Nicolas Vauthey et al.
ANNALS OF SURGERY (2013)
Cancer statistics, 2013
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2013)
Incidence and Prognostic Impact of KRAS and BRAF Mutation in Patients Undergoing Liver Surgery for Colorectal Metastases
Georgios Karagkounis et al.
CANCER (2013)
Surgery for colorectal liver metastases: The evolution of determining prognosis
Gaya Spolverato et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2013)
Adjuvant Chemotherapy With FOLFOX for Primary Colorectal Cancer Is Associated With Increased Somatic Gene Mutations and Inferior Survival in Patients Undergoing Hepatectomy for Metachronous Liver Metastases
Andreas Andreou et al.
ANNALS OF SURGERY (2012)
Evolution of Long-Term Outcome of Liver Resection for Colorectal Metastases: Analysis of Actual 5-Year Survival Rates over Two Decades
Luca Vigano et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab
S. Stremitzer et al.
BRITISH JOURNAL OF SURGERY (2012)
BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy
Hao-Wei Teng et al.
JOURNAL OF SURGICAL ONCOLOGY (2012)
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
Timothy S. Maughan et al.
LANCET (2011)
Predictive and Prognostic Markers in Colorectal Cancer
Ben George et al.
CURRENT ONCOLOGY REPORTS (2011)
KRAS Mutation Correlates With Accelerated Metastatic Progression in Patients With Colorectal Liver Metastases
Garrett M. Nash et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
Arnaud D. Roth et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Conditional Survival after Surgical Resection of Colorectal Liver Metastasis: An International Multi-Institutional Analysis of 949 Patients
Hari Nathan et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2010)
Survival after Hepatic Resection for Metastatic Colorectal Cancer: Trends in Outcomes for 1,600 Patients during Two Decades at a Single Institution
Michael G. House et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2010)
Timing of Multimodality Therapy for Resectable Synchronous Colorectal Liver Metastases: A Retrospective Multi-Institutional Analysis
Srinevas K. Reddy et al.
ANNALS OF SURGICAL ONCOLOGY (2009)
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F. Loupakis et al.
BRITISH JOURNAL OF CANCER (2009)
Systematic review of tumour number and outcome after radical treatment of colorectal liver metastases
M. D. Smith et al.
BRITISH JOURNAL OF SURGERY (2009)
Cancer Statistics, 2009
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial
Susan D. Richman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
J. Randolph Hecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
Carsten Bokemeyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Recurrent KRAS Codon 146 mutations in human colorectal cancer
Sarah Edkins et al.
CANCER BIOLOGY & THERAPY (2006)
Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study
HJN Andreyev et al.
BRITISH JOURNAL OF CANCER (2001)
Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases
H Petrowsky et al.
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY (2001)
Share Paper
